Bioperfectus and Emergo by UL Reached Annual Strategic Partnership

Company news


Bioperfectus, a leading molecular diagnostic supplier in the global market has formed strategic alliance with Emergo by UL, a pioneering regulatory consulting firm specialized in global medical device and IVD compliance. The partnership will significantly improve the efficiency of regulatory and registration process and greatly shorten the time of market access for Bioperfectus products in 180+ countries around the globe.


After successfully entering into the capital market at the end of 2019, Bioperfectus decided to start a new era of global development.  Through the close cooperation with international regulatory and compliance agency, Bioperfectus has taken a step further to expand its global reach.


In the near future, Bioperfectus will continue to advance the knowledge in specific local IVD market and make greater contribution to a healthier life for the mankind.



Bioperfectus Emergency Response to the Unknown Hepatitis in Children

On 15 April 2022, the World Health Organization (WHO) published an alert on severe acute hepatitis cases of unknown origin in children in the United Kingdom. Since then, there have been continuing additional reports of cases.


Compact and Powerful, SSNP-2000B Promotes Molecular Detection Ability

After SSNP-2000B got the IF award, its application in nucleic acid detection grew with stronger momentum. Conquering the judges with exclusive features, SSNP-2000B also obtained more and more recognition from clinical operators.


Stop Loss from A Small Bite

Vectors are living organisms that can transmit infectious pathogens between humans, or from animals to humans. When a vector becomes infectious, it can transmit the pathogen for the rest of its life during each subsequent bite/blood meal.